A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.
Central nervous system relapse of diffuse large B-cell lymphoma remains uncommon but catastrophic. The benefit of stand-alone intrathecal prophylaxis in reducing central nervous system recurrence is unclear and remains controversial. No systematic review analysing the evidence for stand-alone intrathecal prophylaxis has been performed in the era of anti-CD20 monoclonal antibody therapy. A comprehensive search (01/2002-01/2019) was systematically performed using Ovid MEDLINE, Ovid EMBASE® and Cochrane. Studies were selected from 804 screened based on predefined inclusion/exclusion criteria, and were critically appraised. 3 post hoc analyses (RICOVER-60, RCHOP-14/21, GOYA), 1 prospective database and 10 retrospective series were included. 7357 rituximab/obinutuzumab-exposed patients were analysed. The median percentage receiving intrathecal prophylaxis was 11.9%. Cumulative central nervous system relapse incidence ranged from 1.9% at 6.5 years to 8.4% at 5 years. Median time (of medians) to central nervous system relapse was 10 months. 73% developed isolated central nervous system relapses, 24% concurrent central nervous system/systemic relapse, and 3% post-systemic relapse. Reported central nervous system relapse sites were: parenchymal (58%), leptomeningeal (27%), and both (12%). Event rates were low resulting in limited power within each study to provide robust univariable/multivariable analysis. Intrathecal prophylaxis was not a univariable or multivariable factor associated with a reduction in central nervous system relapse in any study. We found no strong evidence for the benefit, or indeed genuine lack of benefit, of stand-alone intrathecal prophylaxis in preventing central nervous system relapse in diffuse large B-cell lymphoma-treated patients using anthracycline-based immunochemotherapy. Current published study designs limit the strength of such conclusions.